Equazen® Reaffirms Its Commitment to Uncompromising Quality and Sustainability in Omegas Supplements
LUGANO, Switzerland--(BUSINESS WIRE)--Jun 26, 2025--
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, highlights today its ongoing commitment to delivering the highest standard of quality for Equazen ®, the company's global science-based food supplement brand designed to nourish, enhance and support the brain's potential.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625554235/en/
Equazen® continues to set the benchmark for excellence at every step of the value chain
At SFI Health™, quality is more than a requirement—it is a mission. The company is committed to enhancing people's well-being by developing natural supplements that combine passion for nature-based healthcare, science, state-of-the-art production standards and sustainability, from ingredient sourcing to the final product reaching the patient.
In particular, with over 25 years of trust built across multiple markets, Equazen ® 's excellence is built on five core pillars:
'Our mission with Equazen ® is to provide natural supplements that parents and caregivers can trust to support cognitive needs and the health of human brain,' said Matthew Brabazon, General Manager at SFI Health™ EMEA. 'This is made possible only through ethical sourcing, advanced manufacturing, and robust scientific validation.'
As market demands evolve, Equazen ® remains dedicated to pushing quality standards further at every step of the value chain to offer best-in-class solutions for optimal cognitive health. Consumers can trust that every product reflects a passion for health, innovation, and sustainability.
About SFI Health™
SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.
Guided by the belief in the healing potential of natural products, SFI Health™ combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.
An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.
SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.
For more information, go to sfihealth.com or follow us SFI Health on LinkedIn.
About Equazen®
Equazen ® is a science-based globally branded food supplement designed and studied to help nourish, enhance, and support the human brain's potential across all life stages.
Each product of the Equazen ® range contains a balanced unique combination of essential fatty acids (Omega-3 and Omega-6), which has been clinically proven for more than 20 years to assist with learning capabilities, concentration and healthy brain development.
Equazen ® is available in multiple pharmaceutical formats and sizes to support optimal cognitive functions from infants to teenagers.
Currently marketed in 30 countries globally, Equazen ® is widely recommended by healthcare professionals and trusted by families for the last 25 years.
Equazen ® aims to advance human health naturally, delivering expertly formulated products that empower individuals to reach their cognitive potential.
For more info visit www.equazen.com
View source version on businesswire.com:https://www.businesswire.com/news/home/20250625554235/en/
CONTACT: For more information
SFI Health™ EMEA Contact
Elisabetta Bianchi
e-mail address:[email protected]
KEYWORD: SWITZERLAND EUROPE
INDUSTRY KEYWORD: HEALTH ENVIRONMENT SUSTAINABILITY FITNESS & NUTRITION GENERAL HEALTH VITAMINS/SUPPLEMENTS
SOURCE: SFI Health
Copyright Business Wire 2025.
PUB: 06/26/2025 02:00 AM/DISC: 06/26/2025 01:59 AM
http://www.businesswire.com/news/home/20250625554235/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
12 hours ago
- Associated Press
Groups Representing Patients, Healthcare Professionals and Pharmaceutical Industry Author New Principle on Use of AI In Healthcare
GENEVA--(BUSINESS WIRE)--Jun 26, 2025-- Six leading international organizations representing patients, physicians, pharmacists, nurses, hospitals, and the pharmaceutical industry have today adopted the first joint ethical principle in the healthcare industry on the responsible use of health data and technology, including artificial intelligence. This press release features multimedia. View the full release here: The new principle joins the International Consensus Framework for Ethical Collaboration (ICF), a longstanding principles-based voluntary agreement that guides ethical collaboration across these major healthcare bodies, working together to deliver high quality care for patients. The ICF was established in 2014 as a global platform to ensure that relationships across the health ecosystem are grounded in ethical, transparent, and responsible decision-making. It unites six leading health bodies representing patient organizations, healthcare professionals, and the pharmaceutical industry. The founding principles of the ICF focus on prioritizing patients; supporting ethical research and innovation; ensuring independence and ethical conduct; and promoting transparency and accountability. The new fifth principle focuses on autonomy, data stewardship, and shared accountability in the use of health data. This reflects the growing importance of digital health and AI, and the need for ethical considerations to evolve alongside scientific innovation. 'No single hospital or stakeholder can navigate today's rapid advances in health data and technology alone,' said Ronald Lavater, CEO of the International Hospital Federation. 'The ICF enables collective action, empowering global health leaders to build trusted partnerships that unlock the full potential of ethical, person-centered innovation.' 'Data and technology may evolve care delivery, but ethics guides our why, how and for whom,' said Howard Catton, CEO of the International Council of Nurses. 'This principle affirms the enduring importance of trust, compassion, and dignity — values nurses uphold every day across health systems worldwide.' Patient voices are central to the adoption of this principle. 'This new principle is a major step forward in safeguarding the rights of patients and people with lived experience in the digital age,' said Dani Mothci, CEO of the International Alliance of Patients' Organizations. 'As a founding member of the ICF, IAPO welcomes the clear ethical commitment around autonomy, data stewardship, and accountability highlighting focus on putting patients first. To make this a reality, we encourage patient organizations to actively engage with this principle and ensure its implementation reflects real-world patient experiences.' 'Ethics is the cornerstone of effective global health policy. It ensures that decisions are guided by fairness, respect, and accountability. The World Medical Association believes that ethical collaboration is essential to building resilient health systems and delivering better care to all, especially the most vulnerable,' said Dr. Ashok Philip, President of the World Medical Association. Paul Sinclair, President of the International Pharmaceutical Federation, called on pharmacy professionals to embrace the new principle: 'FIP supports ethical and responsible decision making, which involves pharmacy practitioners in relation to patients, healthcare professionals, and the pharmaceutical sector to ensure high-quality care. I invite all our members to adopt and adapt this framework at the country and regional levels of practice.' David Reddy, Director General of the International Federation of Pharmaceutical Manufacturers and Associations, echoed the call for collective responsibility: 'For the past decade, the ICF has fostered stronger alliances and shared values between key partners involved in healthcare delivery, through sustained engagement on emerging ethical challenges. Today, by integrating a new principle on digital health and AI, we're echoing a growing consensus: as innovation accelerates, ethical collaboration must evolve in tandem. Our focus is on delivering for patients — first and always.' ++ ENDS ++ Notes to editors View source version on CONTACT: Media contacts For more information on the ICF and new principle, please contact the following member organization representatives:IFPMA: Ana-Maria Nia,[email protected] ICN: Pilar Millan,[email protected] IAPO: Rachel Githinji,[email protected] IHF: Katherine Bennett,[email protected] WMA: Magda Mihaila,[email protected] FIP: Aysu Selçuk,[email protected] KEYWORD: SWITZERLAND EUROPE INDUSTRY KEYWORD: NURSING DATA MANAGEMENT HEALTH TECHNOLOGY HOSPITALS ARTIFICIAL INTELLIGENCE PHARMACEUTICAL SOURCE: IFPMA Copyright Business Wire 2025. PUB: 06/26/2025 08:00 AM/DISC: 06/26/2025 08:02 AM
Yahoo
12 hours ago
- Yahoo
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile- -Complete Phase 1 data presentation for CTX310 anticipated at a medical meeting in the second half of 2025- -Data update for CTX320™, targeting the LPA gene, now expected in the first half of 2026- -Preclinical in vivo cardiovascular program CTX340™ advancing toward IND / CTA filings targeting refractory hypertension- ZUG, Switzerland and BOSTON, June 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases today announced updates across its in vivo cardiovascular disease programs. These include new data for CTX310™, targeting ANGPTL3, as well as continued progress on CTX320™, targeting the LPA gene, and CTX340™, targeting the AGT gene. 'CRISPR Therapeutics remains focused on executing against our strategic priorities and advancing our portfolio of innovative therapies,' said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. 'The additional data from our ongoing Phase 1 clinical trial for CTX310 reinforces the potential of our platform to transform the treatment of serious cardiovascular diseases. We are progressing with our dose-finding study and expect to share complete data at a medical meeting in the second half of this year. For CTX320, we are continuing our dose-finding study and anticipate sharing data in the first half of 2026, reflecting a strategic decision to incorporate emerging insights from the evolving Lp(a) treatment landscape.' CTX310, targeting CTX310 targets ANGPTL3, a gene that encodes for key protein involved in the regulation of low-density lipoprotein (LDL) and triglyceride (TG) levels – both of which are recognized risk factors for atherosclerotic heart disease (ASCVD). Loss-of-function mutations in ANGPTL3 are associated with significantly reduced levels of LDL and TGs, as well as reduced risk of ASCVD, without known adverse health effects. More than 40 million patients in the U.S. alone are affected by elevated LDL, severely elevated TG or both – representing a significant unmet need and a large addressable population. CTX310 is initially focused on high-risk patients with the greatest unmet medical need and limited effective treatment options. CTX310 is in an ongoing Phase 1 first-in-human clinical trial targeting ANGPTL3 in four patient groups: homozygous familial hypercholesterolemia (HoFH), severe hypertriglyceridemia (sHTG), heterozygous familial hypercholesterolemia (HeFH), or mixed dyslipidemias (MDL). Eligible participants have levels of TG >300 mg/dL and/or LDL-C >100 mg/dL (or >70 mg/dL for subjects with ASCVD). Both LDL and TG are validated surrogate endpoints accepted by regulatory agencies. These new results build upon previously disclosed results from the first 10 patients across the first four cohorts (lean body weight-based doses of DL1 [0.1 mg/kg], DL2 [0.3 mg/kg], DL3 [0.6 mg/kg] and DL4 [0.8 mg/kg]) with at least 30 days of follow-up for each participant. As dose-range finding continues, data to date demonstrate peak reductions of up to 82% in TG and LDL reductions of up to 86% at DL4 without any clinically significant changes in liver enzymes and a safety and tolerability profile consistent with previous findings. The Company anticipates presenting the complete Phase 1 data for CTX310 at a medical meeting in the second half of 2025. CTX320™, targeting CTX320 is in an ongoing Phase 1 clinical trial targeting the LPA gene in patients with elevated lipoprotein(a) [Lp(a)], a genetically determined risk factor associated with increased incidence of major adverse cardiovascular events (MACE). Elevated Lp(a) levels affect up to 20% of the global population and remains unaddressed by current therapies. The Phase 1 trial is enrolling patients and dose-finding is ongoing. An update is now expected in the first half of 2026, reflecting a strategic decision to incorporate emerging insights from the evolving Lp(a) landscape. CTX340, targeting angiotensinogen (AGT) CRISPR Therapeutics is also advancing its preclinical in vivo cardiovascular program CTX340, targeting angiotensinogen (AGT) for the treatment of refractory hypertension. CTX340 is currently progressing through IND/CTA-enabling studies. About ProgramsCRISPR Therapeutics has established a proprietary lipid nanoparticle (LNP) platform for the delivery of CRISPR/Cas9 to the liver. The Company's in vivo portfolio includes its lead investigational programs, CTX310 (directed towards angiopoietin-related protein 3 (ANGPTL3)) and CTX320 (directed towards LPA, the gene encoding apolipoprotein(a) (apo(a)), a major component of lipoprotein(a) [Lp(a)]). Both are validated therapeutic targets for cardiovascular disease. CTX310 and CTX320 are in ongoing clinical trials in patients with heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemias, or severe hypertriglyceridemia, and in patients with elevated lipoprotein(a), respectively. In addition, the Company's research and preclinical development candidates include CTX340 and CTX450™, targeting angiotensinogen (AGT) for refractory hypertension and 5'-aminolevulinate synthase 1 (ALAS1) for acute hepatic porphyria (AHP), respectively. About CRISPR TherapeuticsSince its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit CRISPR THERAPEUTICS® standard character mark and design logo CTX310™, CTX320™, CTX340™ and CTX450™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners. CRISPR Special Note Regarding Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements made by Dr. Kulkarni in this press release, as well as regarding any or all of the following: (i) CRISPR Therapeutics preclinical studies, clinical trials and pipeline products and programs, including, without limitation, status of such studies and trials (including guidance) and expectations regarding data, safety and efficacy generally; (ii) data included in this press release, as well as the ability to use data from ongoing and planned clinical trials for the design and initiation of further clinical trials; (iii) regulatory submissions and authorizations, including related timelines; and (iv) the therapeutic value, development, and commercial potential of gene editing and delivery technologies and therapies, including CRISPR/Cas9. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading 'Risk Factors' in its most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law. This press release also contains information regarding our industry, our business and the markets for certain of our product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Unless otherwise expressly stated, we obtained this industry, business, market and other data from market research firms and other third parties, including medical publications, government data and similar sources. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. This press release discusses CRISPR/Cas9 gene editing investigational therapies and is not intended to convey conclusions about efficacy or safety as to those investigational therapies or uses of such investigational therapies. There is no guarantee that any investigational therapy will successfully complete clinical development or gain approval from applicable regulatory authorities. Investor Contact:+1-617-307-7503ir@ Media Contact:+1-617-315-4493media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
18 hours ago
- Associated Press
Equazen® Reaffirms Its Commitment to Uncompromising Quality and Sustainability in Omegas Supplements
LUGANO, Switzerland--(BUSINESS WIRE)--Jun 26, 2025-- SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, highlights today its ongoing commitment to delivering the highest standard of quality for Equazen ®, the company's global science-based food supplement brand designed to nourish, enhance and support the brain's potential. This press release features multimedia. View the full release here: Equazen® continues to set the benchmark for excellence at every step of the value chain At SFI Health™, quality is more than a requirement—it is a mission. The company is committed to enhancing people's well-being by developing natural supplements that combine passion for nature-based healthcare, science, state-of-the-art production standards and sustainability, from ingredient sourcing to the final product reaching the patient. In particular, with over 25 years of trust built across multiple markets, Equazen ® 's excellence is built on five core pillars: 'Our mission with Equazen ® is to provide natural supplements that parents and caregivers can trust to support cognitive needs and the health of human brain,' said Matthew Brabazon, General Manager at SFI Health™ EMEA. 'This is made possible only through ethical sourcing, advanced manufacturing, and robust scientific validation.' As market demands evolve, Equazen ® remains dedicated to pushing quality standards further at every step of the value chain to offer best-in-class solutions for optimal cognitive health. Consumers can trust that every product reflects a passion for health, innovation, and sustainability. About SFI Health™ SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing. Guided by the belief in the healing potential of natural products, SFI Health™ combines a rigorous pharma-based approach with the benefits of naturally sourced solutions. An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa. SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide. For more information, go to or follow us SFI Health on LinkedIn. About Equazen® Equazen ® is a science-based globally branded food supplement designed and studied to help nourish, enhance, and support the human brain's potential across all life stages. Each product of the Equazen ® range contains a balanced unique combination of essential fatty acids (Omega-3 and Omega-6), which has been clinically proven for more than 20 years to assist with learning capabilities, concentration and healthy brain development. Equazen ® is available in multiple pharmaceutical formats and sizes to support optimal cognitive functions from infants to teenagers. Currently marketed in 30 countries globally, Equazen ® is widely recommended by healthcare professionals and trusted by families for the last 25 years. Equazen ® aims to advance human health naturally, delivering expertly formulated products that empower individuals to reach their cognitive potential. For more info visit View source version on CONTACT: For more information SFI Health™ EMEA Contact Elisabetta Bianchi e-mail address:[email protected] KEYWORD: SWITZERLAND EUROPE INDUSTRY KEYWORD: HEALTH ENVIRONMENT SUSTAINABILITY FITNESS & NUTRITION GENERAL HEALTH VITAMINS/SUPPLEMENTS SOURCE: SFI Health Copyright Business Wire 2025. PUB: 06/26/2025 02:00 AM/DISC: 06/26/2025 01:59 AM
